Literature DB >> 4028729

Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake.

F Loogen, H Worth, G Schwan, G Goeckenjan, B Lösse, D Horstkotte.   

Abstract

Over a period of up to 18 years, 24 patients (mean age: 33.8 years) with primary vascular pulmonary hypertension (PVPH) of unknown aetiology (group A) and 18 subjects (mean age: 45.3 years) with PVPH due to anorectic drug intake (group B) were comparatively studied. The following main tendencies became apparent: 1) The 10-year cumulative survival rate in group A (0.31) was lower than in group B (0.63). 2) Patients of group A showed more marked X-ray and ECG signs of pulmonary hypertension and right ventricular hypertrophy in comparison with group B. In contrast to group B, the ECG signs of hypertrophy in group A increased during the observation period. 3) Mean pulmonary artery pressure (PAP) significantly increased in group A (from 48.8 to 61.0 mmHg), while it decreased (from 47.6 to 33.3 mmHg) in group B. 4) The diameter of the descending branch of the right pulmonary artery increased with rising PAP only in group A, while the relationship between PAP and the Sokolow-Lyon index was significant only for the whole group of PVPH patients but not for the subgroups A and B. A regression of pulmonary hypertension in patients with anorectic drug intake was obvious, in contrast to the course in patients with PVPH of unknown aetiology.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028729

Source DB:  PubMed          Journal:  Cor Vasa        ISSN: 0010-8650


  5 in total

Review 1.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 2.  Safety of drug therapies used for weight loss and treatment of obesity.

Authors:  Lisa L Ioannides-Demos; Joseph Proietto; Andrew M Tonkin; John J McNeil
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Appetite suppressants and primary pulmonary hypertension in the United Kingdom.

Authors:  S H Thomas; A Y Butt; P A Corris; J J Egan; T W Higenbottam; B P Madden; P C Waller
Journal:  Br Heart J       Date:  1995-12

4.  Primary pulmonary hypertension and fenfluramine use.

Authors:  F Brenot; P Herve; P Petitpretz; F Parent; P Duroux; G Simonneau
Journal:  Br Heart J       Date:  1993-12

Review 5.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.